Connect with us

Hi, what are you looking for?

Thursday, Mar 20, 2025
Mugglehead Investment Magazine
Alternative investment news based in Vancouver, B.C.
'Bioptimus' raises millions to develop biology expert AI bot
'Bioptimus' raises millions to develop biology expert AI bot
Bioptimus Chief Operating Officer, Mathilda Strom, speaks at Finland's SLUSH 2024 tech startup conference in November. Photo credit: Bioptimus

AI and Autonomy

‘Bioptimus’ raises millions to develop biology expert AI bot

The French startup has described it as the ‘GPT of biology’ and it’s slated to be released by the end of the year

A science-focused French seed company has secured another US$41 million to propel development of what it describes as the “GPT of biology.”

The new funding round, led by San Francisco’s venture capital firm Cathay Innovation, brings the startup’s total funding to US$76 million.

“The funding will accelerate Bioptimus’s mission to build the world’s first universal AI foundation model for biology,” the startup explained in a press release on Tuesday, “aimed at revolutionizing research and innovation across the medical, biotech, cosmetic industries, and beyond.”

The news follows Bioptimus releasing an AI model specializing in disease know-how last summer. The debut of “H-Optimus-0” was a major development in the pathology field.

The Chief Technical Officer of Bioptimus, Rodolphe Jenatton, was formerly a senior research scientist at Google. Additionally, multiple members of the company’s founding team previously served as researchers at Google DeepMind.

The AI-biotech company Owkin, also based in France, was instrumental in the creation of Bioptimus too, and it is providing a vast trove of data to help train the new biotech bot.

Bioptimus’s CEO, Jean-Philippe Vert, is Owkin’s Chief R&D Officer.

Read more: ‘They took our jobs!’: AI will replace many of us by 2030, WEF finds

Read more: Scottish AI company develops image-to-sound tech, makes life easier for content creators

COO speaks at top startup and tech event in Helsinki

Mathilda Strom hit the stage at the SLUSH 2024 conference in Finland’s capital city in November to enlighten attendees about the company’s biology and artificial intelligence aspirations.

She also discussed the financial challenges that many startup companies face due to economic turbulence and rising interest rates.

“While I hope to see some stabilization in funding conditions next year, I remain cautious,” the chief operating officer said. Strom was appointed to the position only weeks before she attended the event.

Many other French startups made their way to Slush too. These include the microbiology-focused company Ebiose; the clean energy specialist Leviathan Dynamics; and the cybersecurity expert Prelude.

Over 13,000 people attended the prominent event last year.

 

Follow Mugglehead on X

Like Mugglehead on Facebook

Follow Rowan Dunne on X

rowan@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

AI and Autonomy

The robot will provide end-to-end intelligent automation, using AI-driven precision to integrate preoperative 3D lesion segmentation

Bitcoin

Bitfarms' acquisition supports its broader goal of expanding in North America

AI and Autonomy

Researchers must test quantum computing against classical computers in real-world scenarios to validate its capabilities

AI and Autonomy

This deal will generate short-term financial gains for the company while positioning Gorilla as a key player